Clinical Trials Arena November 15, 2023
Chikungunya is a mosquito-borne disease, characterised by fever, severe joint pain, headache, nausea, fatigue, and rash.
Valneva recently announced the approval of IXCHIQ by the FDA, marking the world’s first approved chikungunya vaccine. IXCHIQ is a single-dose, live-attenuated vaccine for use in adults 18 years of age and older, for the prevention of disease caused by the chikungunya virus (CHIKV). IXCHIQ has the potential to mitigate a major public health threat and prevent millions of cases of chikungunya worldwide.
Chikungunya is a mosquito-borne disease, characterised by fever, severe joint pain, headache, nausea, fatigue, and rash, that has been identified in over 110 countries across Asia, Africa, Europe, and the Americas. Despite the significant disease burden, there are currently no treatment...
Today's Sponsors
Today's Sponsor